Bortezomib use and outcomes for the treatment of multiple myeloma.

Crystal LokePeter MolleeIan McPhersonEuan WalpoleMimi YueHoward MutsandoPhillip WongHelen WestonRoss TomlinsonSamantha A Hollingworth

Published in: Internal medicine journal (2021)

Our patients were older, had worse disease characteristics and more comorbidities than patients in the VISTA trial. While response rates were similar, survival outcomes appeared worse. Bortezomib-based treatment in the real world setting still carries a high risk of toxicity in the elderly population.

Keyphrases

newly diagnosed
multiple myeloma
end stage renal disease
ejection fraction
chronic kidney disease
clinical trial
type diabetes
oxidative stress
metabolic syndrome
physical activity
middle aged